Hesham Mohamed, MD

Regeneron Pharmaceuticals, Inc.

Poster(s):

• ((SLA-025)) (SLA-025) Second Primary Malignancy in Patients with Diffuse Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy and Other Systemic Anti-Cancer Therapy: A Real-World Evidence from a Large US National Claims Database
  Sunday, August 24, 2025

  12:15 PM - 1:15 PM ET